Evidence map›Paper›PMID 37210151›Full record

ArticleArtificial intelligence in medicine2023

A unique color-coded visualization system with multimodal information fusion and deep learning in a longitudinal study of Alzheimer's disease.

Mohammad Eslami, Solale Tabarestani, Malek Adjouadi

Abstract read
In one paragraph

Article in Artificial intelligence in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammad EslamiHarvard Ophthalmology AI lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Center for Advanced Technology and Education, Florida International University, Miami, FL, United States. Electronic address: Mohammad_eslami@meei.harvard.edu.
Solale TabarestaniCenter for Advanced Technology and Education, Florida International University, Miami, FL, United States. Electronic address: Staba006@fiu.edu.
Malek AdjouadiCenter for Advanced Technology and Education, Florida International University, Miami, FL, United States. Electronic address: adjouadi@fiu.edu.

Funding

Social Determinants of Health, Race/Ethnicity, and White Matter HyperintensitiesP30AG066506 · NIA · UNIVERSITY OF FLORIDA · PI Rosie E Curiel Cid · 2020 to 2026
$25.6M
A Novel Computerized Cognitive Stress Test Designed for Clinical Trials in Early Alzheimer's: Relationship with Multimodal Imaging Biomarkers in Diverse Cultural GroupsR01AG061106 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOEWENSTEIN, DAVID · 2019 to 2023
$3.6M
Novel Detection of Early Cognitive and Functional Impairment in the ElderlyR01AG047649 · NIA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOEWENSTEIN, DAVID · 2015 to 2019
$2.7M
NIA NIH HHS P30 AG066506NIA NIH HHS R01 AG047649NIA NIH HHS R01 AG061106
6 · The paper itself

Abstract

purposeAutomated diagnosis and prognosis of Alzheimer's Disease remain a challenging problem that machine learning (ML) techniques have attempted to resolve in the last decade. This study introduces a first-of-its-kind color-coded visualization mechanism driven by an integrated ML model to predict disease trajectory in a 2-year longitudinal study. The main aim of this study is to help capture visually in 2D and 3D renderings the diagnosis and prognosis of AD, therefore augmenting our understanding of the processes of multiclass classification and regression analysis.

methodThe proposed method, Machine Learning for Visualizing AD (ML4VisAD), is designed to predict disease progression through a visual output. This newly developed model takes baseline measurements as input to generate a color-coded visual image that reflects disease progression at different time points. The architecture of the network relies on convolutional neural networks. With 1123 subjects selected from the ADNI QT-PAD dataset, we use a 10-fold cross-validation process to evaluate the method. Multimodal inputs* include neuroimaging data (MRI, PET), neuropsychological test scores (excluding MMSE, CDR-SB, and ADAS to avoid bias), cerebrospinal fluid (CSF) biomarkers with measures of amyloid beta (ABETA), phosphorylated tau protein (PTAU), total tau protein (TAU), and risk factors that include age, gender, years of education, and ApoE4 gene. FINDINGS/

resultsBased on subjective scores reached by three raters, the results showed an accuracy of 0.82 ± 0.03 for a 3-way classification and 0.68 ± 0.05 for a 5-way classification. The visual renderings were generated in 0.08 msec for a 23 × 23 output image and in 0.17 ms for a 45 × 45 output image. Through visualization, this study (1) demonstrates that the ML visual output augments the prospects for a more accurate diagnosis and (2) highlights why multiclass classification and regression analysis are incredibly challenging. An online survey was conducted to gauge this visualization platform's merits and obtain valuable feedback from users. All implementation codes are shared online on GitHub.

conclusionThis approach makes it possible to visualize the many nuances that lead to a specific classification or prediction in the disease trajectory, all in context to multimodal measurements taken at baseline. This ML model can serve as a multiclass classification and prediction model while reinforcing the diagnosis and prognosis capabilities by including a visualization platform.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDeep LearningAmyloid beta-PeptidesDisease ProgressionHumansLongitudinal StudiesMagnetic Resonance Imagingtau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer's diseaseDeep learningDiagnosisPrognosisTrustfulness visualization

Identifiers

PMID37210151
PMCPMC10204620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.